baricitinib

Potential blockbuster arthritis drug delayedCiting safety concerns, FDA delayed approval of a new blockbuster drug to treat rheumatoid arthritis.
Three drug trends impacting specialty pharmacyAMCP session, “Specialty Pharmaceutical in Development,” highlighted critical trends that healthcare executives should be watching
New rheumatoid arthritis therapies are comingFour new drugs and a biosimilar should be on your radar.